Table 1

Clinical and demographic characteristics of breast cancer patients treated with FEC/TX (n=66) and FEC/TX plus H (n=25)
Characteristic 66 patients treated with FEC/TX 25 patients treated with FEC/TX plus H
pCR No. cases (%) RD No. cases (%) pCR No. cases (%) RD No. cases (%)
All patients 25 (100) 41 (100) 12(100) 13 (100)
Age in yrs
Median (range) 49 (34-69) 49 (26- 67) 50 (37-59) 49 (39-64)
Histology
Invasive ductal (IDC) 24 (96.0) 38 (92.7) 12 (100.0) 12 (92.3)
Invasive lobular (ILC) 0 (0.0) 1 (2.4) 0 (0.0) 0 (0.0)
Invasive mucinous (IMC) 0(0.0) 1 (2.4) 0(0.0) 0 (0.0)
NOS 1 (4.0) 1 (2.4) 0 (0.0) 1 (7.7)
Clinical tumor size at baseline
T1 0 (0) 1 (2.4) 0 (0.0) 0 (0.0)
T2 9 (36.0) 14 (34.1) 4 (33.3) 7 (53.8)
T3 14 (56.0) 23 (56.1) 6 (50.0) 4 (30.8)
T4 2 (8.0) 3 (7.3) 2 (16.7) 2(15.4)
Clinical node status at baseline
N0 8 (32.0) 15 (36.6) 2 (16.7) 4 (30.8)
N1 12 (48.0) 22 (53.7) 7(58.3) 4 (30.8)
N2 2 (8.0) 2 (4.9) 1 (8.3) 4 (30.8)
N3 3 (12.0) 1 (2.4) 1 (8.3) 0 (0.0)
Unkown 1 (8.3) 1 (7.7)
Histologic Grade
1 & 2 4 (16.0) 10 (24.4) 6 (50.0) 3 (23.1)
3 14 (56.0) 26 (63.4) 4 (33.3) 9 (69.2)
Unknown 7 (28.0) 5 (12.2) 2 (16.7) 1 (7.7)
ER status
Positive1 8 (32.0) 20 (48.8) 2 (1.7) 8 (61.5)
Negative 17 (68.0) 20 (48.8) 10 (76.9) 5 (38.5)
Unknown 0 (0.0) 1 (2.4)
HER-2 status
Positive 2 5 (20.0) 5 (12.2) 13 (100) 12 (92.3)
Negative 20 (80.0) 33 (80.5) 0 (0.0) 1 (7.7)
Unknown 0 (0.0) 3 (7.3) 0 (0.0) 0 (0.0)

1Cases where >10% of tumor cells stained positive for ER with immunohistochemistry were considered positive. 2Cases that showed either 3+ IHC staining or had gene copy number >2.0 were considered HER2-positive.

Shen et al.

Shen et al. BMC Medical Genomics 2012 5:51   doi:10.1186/1755-8794-5-51

Open Data